Lung-Targeted LNP Development (Case Study)

Delivering RNA to the lung is difficult due to strong physiological barriers, rapid mucociliary clearance, and the natural tendency of LNPs to accumulate in the liver. Overcoming these obstacles requires specialized shielding chemistries and precise ligand‑mediated targeting strategies. 

 PEG‑free polymers such as PSar reduce immunogenicity concerns and avoid anti‑PEG responses while maintaining stealth behavior. They also allow higher ligand loading, giving developers more flexibility to engineer LNPs for extrahepatic delivery. 

Peptides offer high receptor specificity, tunable affinity, and low immunogenicity. These properties make them ideal for enhancing cellular uptake and directing LNPs to tissues like the lung, where receptor‑mediated entry can significantly boost delivery efficiency. 

 Shielding polymers influence protein corona formation, circulation time, and immune recognition. By modulating these interactions, they help LNPs avoid liver sequestration and improve access to peripheral tissues. 

 The spatial presentation of ligands on the LNP surface determines how effectively they can engage target receptors. Proper orientation enhances binding strength, increases uptake, and reduces competition from nonspecific interactions. 

 Stability depends on lipid composition, conjugation chemistry, ligand density, and the physicochemical balance between hydrophobic and hydrophilic components. These parameters collectively influence particle integrity, dispersity, and in vivo performance. 

Lung‑directed RNA delivery is particularly valuable for treating respiratory genetic disorders, pulmonary infections, localized inflammation, and systemic diseases where selective lung accumulation enhances therapeutic precision and safety.